Eli Lilly and Company (LLY)vsOrganogenesis Holdings Inc (ORGO)
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
ORGO
Organogenesis Holdings Inc
$2.35
+2.17%
HEALTHCARE · Cap: $307.45M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 11453% more annual revenue ($65.18B vs $564.17M). LLY leads profitability with a 31.7% profit margin vs 6.6%. ORGO trades at a lower P/E of 15.9x. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
ORGO
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+80.1%
Fair Value
$18.81
Current Price
$2.35
$16.46 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Reasonable price relative to book value
Revenue surging 78.1% year-over-year
Earnings expanding 555.0% YoY
Attractively priced relative to earnings
Strong operational efficiency at 28.9%
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
Smaller company, higher risk/reward
6.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : ORGO
The strongest argument for ORGO centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 78.1% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : ORGO
The primary concerns for ORGO are Market Cap, Profit Margin.
Key Dynamics to Monitor
LLY profiles as a growth stock while ORGO is a hypergrowth play — different risk/reward profiles.
ORGO carries more volatility with a beta of 1.48 — expect wider price swings.
ORGO is growing revenue faster at 78.1% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 67/100), backed by strong 31.7% margins and 42.6% revenue growth. ORGO offers better value entry with a 80.1% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Organogenesis Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures and markets solutions for the advanced wound care and surgical and sports medicine markets in the United States. The company is headquartered in Canton, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?